Japan Study: Weekly vs. Twice-Daily Exenatide for Type 2 Diabetes

Japanese Researchers Compare Two Forms of the Same Diabetes Medication

A study from Japan, published in BMC Endocrine Disorders (2022), examined what happens when patients with type 2 diabetes switch from a twice-daily injectable form of exenatide to a more convenient once-weekly version. The research team at Keio University School of Medicine in Tokyo used continuous glucose monitors (CGMs) and specialized breathing tests to track changes in blood sugar patterns, stomach function, and blood vessel health over 24 weeks.

What Makes This Study Unique

Most US studies on GLP-1 receptor agonists like exenatide focus primarily on HbA1c reduction and weight loss outcomes. This Japanese study goes a step further by examining how and why blood sugar patterns change after switching formulations — specifically by measuring gastric emptying speed (how fast food leaves the stomach) and vascular endothelial function (the health of the inner lining of blood vessels). This more detailed look at the body's response gives patients and clinicians a clearer picture of what's actually happening day to day.

What the Study Found

• HbA1c improved significantly over 24 weeks after switching to the once-weekly formulation — a positive result.
• Post-meal blood sugar rose after both breakfast and dinner (both results were statistically significant, meaning unlikely due to chance).
• Overall blood sugar variability — how much levels fluctuated throughout the day — showed only modest increases and was not statistically significant. In plain terms, day-to-day swings didn't dramatically worsen.
• Stomach emptying sped up significantly — food moved from the stomach to the intestine faster after switching (average time dropped from about 83 minutes to 58 minutes). This faster emptying was directly linked to the higher post-meal glucose spikes.
• Blood vessel health did not significantly change, which is reassuring from a cardiovascular standpoint.

A Note on Measurements

Blood sugar in this study was measured in mmol/L, the standard in Japan. For US patients more familiar with mg/dL, the conversion is simple: multiply mmol/L by 18. For example, a post-meal reading of 8.0 mmol/L equals approximately 144 mg/dL.

How This Compares to US Guidelines

Current American Diabetes Association (ADA) guidelines support once-weekly GLP-1 receptor agonists as effective and convenient treatment options for type 2 diabetes. This study's overall findings align with that guidance — but adds a nuance the ADA also emphasizes: post-meal glucose monitoring matters, especially when changing medications.

Why This Matters for US Patients

If your doctor has recommended switching to a once-weekly GLP-1 medication for convenience, this research suggests the trade-off is generally favorable — better HbA1c with manageable changes in blood sugar variability. However, you may notice higher blood sugar readings after meals, particularly breakfast and dinner. This is likely due to your stomach emptying faster, which causes glucose to enter your bloodstream more quickly. Tracking your post-meal readings with a CGM or regular fingerstick monitoring becomes especially important during any medication transition. Tools and resources available at mdsdiabetes.com can help you understand your glucose patterns and have a more informed conversation with your care team about managing post-meal spikes.

Full Citation

Inaishi, Saisho, Watanabe (2022). Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study. BMC Endocrine Disorders. [Japan — Keio University School of Medicine, Tokyo]. PMID: 35016646. DOI: 10.1186/s12902-022-00932-9